» Articles » PMID: 34820791

A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials

Overview
Journal Methods Inf Med
Publisher Thieme
Date 2021 Nov 25
PMID 34820791
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Data harmonization is essential to integrate individual participant data from multiple sites, time periods, and trials for meta-analysis. The process of mapping terms and phrases to an ontology is complicated by typographic errors, abbreviations, truncation, and plurality. We sought to harmonize medical history (MH) and adverse events (AE) term records across 21 randomized clinical trials in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Methods: We developed and applied a semi-automated harmonization pipeline for use with domain-expert annotators to resolve ambiguous term mappings using exact and fuzzy matching. We summarized MH and AE term mapping success, including map quality measures, and imputation of a generalizing term hierarchy as defined by the applied Medical Dictionary for Regulatory Activities (MedDRA) ontology standard.

Results: Over 99.6% of both MH ( = 37,105) and AE ( = 58,170) records were successfully mapped to MedDRA low-level terms. Automated exact matching accounted for 74.9% of MH and 85.5% of AE mappings. Term recommendations from fuzzy matching in the pipeline facilitated annotator mapping of the remaining 24.9% of MH and 13.8% of AE records. Imputation of the generalized MedDRA term hierarchy was unambiguous in 85.2% of high-level terms, 99.4% of high-level group terms, and 99.5% of system organ class in MH, and 75% of high-level terms, 98.3% of high-level group terms, and 98.4% of system organ class in AE.

Conclusion: This pipeline dramatically reduced the burden of manual annotation for MH and AE term harmonization and could be adapted to other data integration efforts.

Citing Articles

Novel Liver Injury Phenotypes and Outcomes in Clinical Trial Participants with Pulmonary Hypertension.

Scott J, Moutchia J, McClelland R, Al-Naamani N, Weinberg E, Palevsky H Am J Respir Crit Care Med. 2024; 210(8):1045-1056.

PMID: 38820270 PMC: 11531102. DOI: 10.1164/rccm.202311-2196OC.


Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.

Moutchia J, McClelland R, Al-Naamani N, Appleby D, Holmes J, Minhas J Eur Heart J. 2024; 45(21):1937-1952.

PMID: 38416633 PMC: 11143388. DOI: 10.1093/eurheartj/ehae049.


Electrocardiographic Abnormalities and Their Association with Outcomes in Randomized Clinical Trials of Pulmonary Arterial Hypertension.

Minhas J, Moutchia J, Al-Naamani N, Mazurek J, Holmes J, Appleby D Ann Am Thorac Soc. 2024; 21(6):858-865.

PMID: 38241602 PMC: 11160135. DOI: 10.1513/AnnalsATS.202307-609OC.


Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.

Blette B, Moutchia J, Al-Naamani N, Ventetuolo C, Cheng C, Appleby D Lancet Respir Med. 2023; 11(10):873-882.

PMID: 37230098 PMC: 10592525. DOI: 10.1016/S2213-2600(23)00155-8.


Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.

Moutchia J, McClelland R, Al-Naamani N, Appleby D, Blank K, Grinnan D Am J Respir Crit Care Med. 2023; 207(8):1070-1079.

PMID: 36629737 PMC: 10112451. DOI: 10.1164/rccm.202208-1547OC.

References
1.
Simonneau G, Barst R, Galie N, Naeije R, Rich S, Bourge R . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165(6):800-4. DOI: 10.1164/ajrccm.165.6.2106079. View

2.
Sitbon O, Channick R, Chin K, Frey A, Gaine S, Galie N . Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(26):2522-33. DOI: 10.1056/NEJMoa1503184. View

3.
Lachin J . Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981; 2(2):93-113. DOI: 10.1016/0197-2456(81)90001-5. View

4.
Bruland P, Breil B, Fritz F, Dugas M . Interoperability in clinical research: from metadata registries to semantically annotated CDISC ODM. Stud Health Technol Inform. 2012; 180:564-8. View

5.
Galie N, Olschewski H, Oudiz R, Torres F, Frost A, Ghofrani H . Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117(23):3010-9. DOI: 10.1161/CIRCULATIONAHA.107.742510. View